Name: C4 Therapeutics, Inc. (CCCC) Financial Statements
Creator: FinSpry

C4 Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

C4 Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	35.58	20.76	31.10	45.79	33.20
Cost of Revenue	0.00	117.71	117.84	94.67	78.44
Gross Profit	35.58	-96.95	31.10	-48.88	-45.25
Operating Expenses
Research & Development	110.64	117.71	117.84	94.67	0.00
Selling, General & Administrative	42.12	42.08	42.79	33.25	15.20
Operating Expenses	155.20	42.08	160.63	33.25	15.20
Operating Income	-119.61	-139.03	-129.53	-82.13	-60.45
Other Income/Expense
Interest Income	14.43	6.03	3.58	2.27	0.30
Interest Expense	0.00	-1.37	2.22	-2.15	-1.23
Other Income/Expense	14.43	-0.62	5.58	2.93	-5.68
Income
Income Before Tax	-105.19	-131.21	-128.18	-83.89	-66.96
Income Tax Expense	0.13	1.28	0.00	0.00	-0.63
Net Income	-105.32	-132.49	-128.18	-83.89	-66.34
Net Income - Continuous Operations	-105.32	-132.49	-128.18	-83.89	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-103.37	-137.15	-124.28	-80.64	-58.83
EBIT	-105.22	-139.03	-125.96	-82.13	-60.45
Depreciation & Amortization	1.82	1.88	1.68	1.49	1.62
Earnings Per Share
Basic EPS	-2.00	-3.00	-3.00	-2.00	-6.00
Diluted EPS	-2.00	-3.00	-3.00	-2.00	-6.00
Basic Shares Outstanding	69.37	49.64	48.86	46.04	11.37
Diluted Shares Outstanding	69.37	49.64	48.86	46.04	11.37